Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of JPY 2.76 trillion. The enterprise value is 3.40 trillion.

Market Cap	2.76T
Enterprise Value	3.40T

Important Dates

The next estimated earnings date is Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.78% in one year.

Current Share Class	n/a
Shares Outstanding	1.79B
Shares Change (YoY)	-0.78%
Shares Change (QoQ)	+0.11%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	55.27%
Float	1.79B

Valuation Ratios

The trailing PE ratio is 50.68 and the forward PE ratio is 25.79. Astellas Pharma's PEG ratio is 0.34.

PE Ratio	50.68
Forward PE	25.79
PS Ratio	1.56
PB Ratio	1.80
P/TBV Ratio	n/a
P/FCF Ratio	18.02
P/OCF Ratio	n/a
PEG Ratio	0.34

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.34, with an EV/FCF ratio of 22.22.

EV / Earnings	62.18
EV / Sales	1.92
EV / EBITDA	9.34
EV / EBIT	20.20
EV / FCF	22.22

Financial Position

The company has a current ratio of 1.10, with a Debt / Equity ratio of 0.61.

Current Ratio	1.10
Quick Ratio	0.79
Debt / Equity	0.61
Debt / EBITDA	2.56
Debt / FCF	6.11
Interest Coverage	14.19

Financial Efficiency

Return on equity (ROE) is 3.45% and return on invested capital (ROIC) is 4.25%.

Return on Equity (ROE)	3.45%
Return on Assets (ROA)	3.03%
Return on Capital (ROIC)	4.25%
Revenue Per Employee	120.11M
Profits Per Employee	3.71M
Employee Count	14,754
Asset Turnover	0.51
Inventory Turnover	1.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.61% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-7.61%
50-Day Moving Average	1,654.64
200-Day Moving Average	1,636.62
Relative Strength Index (RSI)	38.74
Average Volume (20 Days)	5,480,695

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of JPY 1.77 trillion and earned 54.75 billion in profits. Earnings per share was 30.44.

Revenue	1.77T
Gross Profit	1.45T
Operating Income	169.98B
Pretax Income	57.69B
Net Income	54.75B
EBITDA	365.89B
EBIT	169.98B
Earnings Per Share (EPS)	30.44

Full Income Statement

Balance Sheet

The company has 292.99 billion in cash and 935.83 billion in debt, giving a net cash position of -642.84 billion or -359.10 per share.

Cash & Cash Equivalents	292.99B
Total Debt	935.83B
Net Cash	-642.84B
Net Cash Per Share	-359.10
Equity (Book Value)	1.53T
Book Value Per Share	854.61
Working Capital	109.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 200.80 billion and capital expenditures -47.60 billion, giving a free cash flow of 153.20 billion.

Operating Cash Flow	200.80B
Capital Expenditures	-47.60B
Free Cash Flow	153.20B
FCF Per Share	85.58

Full Cash Flow Statement

Margins

Gross margin is 81.78%, with operating and profit margins of 9.59% and 3.09%.

Gross Margin	81.78%
Operating Margin	9.59%
Pretax Margin	3.26%
Profit Margin	3.09%
EBITDA Margin	20.65%
EBIT Margin	9.59%
FCF Margin	8.65%

Dividends & Yields

This stock pays an annual dividend of 74.00, which amounts to a dividend yield of 4.80%.

Dividend Per Share	74.00
Dividend Yield	4.80%
Dividend Growth (YoY)	10.77%
Years of Dividend Growth	8
Payout Ratio	229.26%
Buyback Yield	0.78%
Shareholder Yield	5.58%
Earnings Yield	1.97%
FCF Yield	5.55%

Dividend Details

Stock Splits

The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2014
Split Type	Forward
Split Ratio	5

Scores

Astellas Pharma has an Altman Z-Score of 1.98. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.98
Piotroski F-Score	n/a